GlassScriptPhysician profile
John D Sprandio
NPI 1144268913
$6,546.34
in general payments reported to CMS, 2019-2025
57 companies · $1,995 in 2025
The $1,995 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $645 · 2020: $573 · 2021: $405 · 2022: $626 · 2023: $986 · 2024: $1,316 · 2025: $1,995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,297.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $978.73 | 2024-2025 | |
| Pfizer INC. | $448.55 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $437.02 | 2019-2025 | Opdivo, Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $326.30 | 2019-2025 | Tagrisso, Imfinzi |
| Novartis Pharmaceuticals Corporation | $310.40 | 2019-2025 | |
| Celgene Corporation | $289.18 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Amgen INC. | $274.65 | 2020-2023 | Nplate, Xgeva, Vectibix |
| Merck Sharp & Dohme LLC | $224.78 | 2019-2025 | Keytruda, Lynparza |
| Seagen INC. | $221.00 | 2019-2023 | Tukysa, Padcev |
| Genentech USA, INC. | $213.32 | 2019-2024 | Venclexta, Erivedge, Alecensa |
| Servier Pharmaceuticals LLC | $183.67 | 2021-2024 | |
| Genzyme Corporation | $182.99 | 2020-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $179.66 | 2021-2025 | |
| Janssen Biotech, INC. | $163.27 | 2019-2025 | Carvykti, Rybrevant, Erleada |
| Eisai INC. | $152.57 | 2020-2024 |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $123.89 | 2023-2025 | Ninlaro, Iclusig, Fruzaqla |
| Pharmacyclics LLC, An Abbvie Company | $122.11 | 2019-2023 | Imbruvica |
| Glaxosmithkline, LLC. | $116.87 | 2023-2025 | Zejula, Jemperli, Ojjaara |
| Daiichi Sankyo INC. | $106.41 | 2020-2025 | Enhertu, Datroway |
| Gilead Sciences, INC. | $96.32 | 2019-2024 | Trodelvy |
| Caris Mpi, INC. | $90.81 | 2025 | Mi Cancer Seek |
| Sumitomo Pharma America, INC. | $83.96 | 2023-2025 | Orgovyx |
| Astellas Pharma US INC | $74.60 | 2024-2025 | Vyloy, Xtandi |
| Aveo Pharmaceuticals, INC. | $70.46 | 2022-2024 | Fotivda |
| Morphosys, US INC. | $69.50 | 2023 | Monjuvi |
| Jazz Pharmaceuticals INC. | $67.99 | 2019-2021 | |
| Abbvie INC. | $64.42 | 2022-2025 | Venclexta |
| Tersera Therapeutics LLC | $58.24 | 2022-2025 | Zoladex |
| Immunocore Limited | $53.76 | 2025 | Kimmtrak |
| Kite Pharma, INC. | $52.86 | 2023-2024 | Yescarta |
| Stemline Therapeutics INC. | $45.40 | 2023-2025 | Orserdu |
| Array Biopharma INC | $44.06 | 2024-2025 | Braftovi, Mektovi, Xalkori |
| Genmab U.S., INC. | $44.05 | 2024 | Tivdak |
| Janssen Pharmaceuticals, INC | $43.72 | 2024 | Xarelto |
| Puma Biotechnology, INC. | $43.31 | 2023-2024 | |
| Rigel Pharmaceuticals, INC. | $40.34 | 2024-2025 | Rezlidhia, Gavreto, Tavalisse |
| Incyte Corporation | $34.24 | 2023-2025 | Pemazyre, Monjuvi |
| Sobi, INC | $32.92 | 2025 | |
| Exelixis INC. | $32.73 | 2022-2025 | Cabometyx |
| Emd Serono, INC. | $32.09 | 2019 | |
| Nuvation Bio INC. | $26.20 | 2025 | Ibtrozi |
| Amneal Pharmaceuticals LLC | $25.61 | 2024 | Avastin |
| Fresenius Kabi USA, LLC | $24.39 | 2022 | |
| G1 Therapeutics, INC. | $23.54 | 2022 | |
| Verastem, INC. | $21.97 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.52 | 2024 | |
| Mirati Therapeutics, INC. | $20.68 | 2023 | Krazati |
| Regeneron Healthcare Solutions, INC. | $20.02 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $19.09 | 2024 | Onivyde |
| Deciphera Pharmaceuticals INC. | $18.55 | 2025 | Qinlock, Romvimza |
| Azurity Pharmaceuticals, INC. | $17.48 | 2025 | Danziten |
| Mylan Institutional INC. | $17.25 | 2020 | |
| Pharmacosmos Therapeutics INC. | $17.20 | 2025 | Monoferric |
| Amag Pharmaceuticals, INC. | $16.39 | 2019 | |
| Spectrum Pharmaceuticals INC. | $13.88 | 2023 | Rolvedon |
| Aurobindo Pharma USA, INC. | $11.42 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sprandio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.